natgillin/translations-raw huggingface dataset:
Median number of DEs requiring substantial intervention adjusted for time at risk (% of patients without DE requiring substantial intervention) Median time to first DE requiring substantial intervention 
Mediana števila PB, kjer je bilo potrebno bistveno posredovanje, korigirano za čas ogroženosti
When administered intravenously, tacrolimus has been shown to have a low clearance rate. 
Ugotovljeno je, da je očistek intravensko uporabljenega takrolimusa majhen.
In both studies, patients with active disease entered an open-label period (OLP) during which they treated affected lesions with tacrolimus ointment twice daily until improvement had reached a predefined score (Investigator's 
V obeh študijah so bolniki z aktivno boleznijo vstopili v odprto obdobje zdravljenja, med katerim so največ 6 tednov uporabljali mazilo s takrolimusom dvakrat na dan, dokler ni izboljšanje kožnih sprememb doseglo vnaprej opredeljene ocene (IGA - Investigator's Global Assessment - raziskovalčeva globalna ocena ≤ 2, to pomeni, da so spremembe izginile, skoraj izginile ali pa gre za blago bolezen).
Two strengths of Protopic (Protopic 0.03% and Protopic 0.1% ointment) are available for adult patients (16 years of age and older). 
Za odrasle bolnike (stare 16 let in več) sta na voljo dve jakosti zdravila Protopic (Protopic 0,03% in Protopic 0,1% mazilo).
1 g of Protopic 0.03% ointment contains 0.3 mg of tacrolimus as tacrolimus monohydrate (0.03%). 
1 g zdravila Protopic 0,03% mazilo vsebuje 0,3 mg takrolimusa v obliki takrolimus monohidrata
Protopic 0.1 % ointment should be applied once a day twice weekly (e.g. Monday and Thursday) to areas of your body commonly affected by atopic dermatitis. 
0,1% mazilo morate enkrat dnevno nanesti na predele telesa, ki jih atopični dermatitis navadno prizadene, in sicer dvakrat v tednu (npr. v ponedeljek in četrtek).
Protopic 0.03% ointment tacrolimus monohydrate Cutaneous use 
Protopic 0,03% mazilo takrolimus monohidrat dermalna uporaba
In a six-month multicentre double-blind randomised trial, 0.1% tacrolimus ointment was administered twice-a-day to adults with moderate to severe atopic dermatitis and compared to a topical corticosteroid based regimen (0.1% hydrocortisone butyrate on trunk and extremities, 1% hydrocortisone acetate on face and neck). 
V šestmesečni multicentrični dvojno slepi randomizirani raziskavi so 0,1-% mazilo s takrolimusom dvakrat na dan aplicirali odraslim z zmernim do hudim atopičnim dermatitisom.
Protopic 0.1% ointment tacrolimus monohydrate Cutaneous use 
Protopic 0,1% mazilo takrolimus monohidrat dermalna uporaba
Application site erythema, Application site pain, Application site irritation, Application site paraesthesia, 
draženje na mestu uporabe, parestezije na mestu uporabe,
Median number of DEs requiring substantial intervention adjusted for time at risk (% of patients without DE requiring substantial intervention) 
(% bolnikov brez PB, kjer bi bilo potrebno bistveno ukrepanje)
1 g of Protopic 0.1% ointment contains 1.0 mg of tacrolimus as tacrolimus monohydrate (0.1%). 
1 g zdravila Protopic 0,1% mazilo vsebuje 1,0 mg takrolimusa v obliki takrolimus monohidrata
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PROTOPIC 0.03% OINTMENT (10 g TUBE) 
OVOJNINAH PROTOPIC 0,03% MAZILO (10 g TUBA)
Once moderate to severe atopic dermatitis is cleared or almost cleared after up to 6 weeks treatment of a flare, and if you are experiencing frequent flares (i.e. 4 or more per year), it may be possible to prevent flares coming back or prolong the time you are free from flares by using Protopic 0.1% ointment twice weekly. 
Ko kožne spremembe zaradi atopičnega dermatitisa izginejo ali skoraj izginejo, vam bo zdravnik morda predpisal, da uporabljajte zdravilo Protopic 0,1% mazilo dvakrat tedensko.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PROTOPIC 0.1% OINTMENT (10 g TUBE) 
OVOJNINAH PROTOPIC 0,1% MAZILO (10 g TUBA)
Tacrolimus 0.1% Twice weekly (N=80) 
Takrolimus dvakrat na teden (n=80)
Protopic ointment should be applied as a thin layer to affected or commonly affected areas of the skin. 
Na prizadete predele kože oziroma na predele kože, ki so navadno prizadeti, je treba nanesti tanko plast zdravila Protopic mazilo.
The primary endpoint was the response rate at month 3 defined as the proportion of patients with at least 60% improvement in the mEASI (modified Eczema Area and Severity Index) between baseline and month 3. 
3 mesecih, določen kot delež bolnikov, ki so v obdobju od izhodišča do 3. meseca doživeli vsaj 60-%
• Risk Management Plan (RMP) Not applicable. 
• Načrt za obvladovanje tveganja (RMP) Navedba smiselno ni potrebna.
Not known: frequency cannot be estimated from the available data 
Neznana: pogostnosti iz razpoložljivih podatkov ni mogoče oceniti
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data). 
Pogostnosti so opredeljene kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in neznana (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
Desloratadine effectively controlled symptoms for 24 hours. 
Desloratadin učinkovito obvladuje te simptome za čas 24 ur.
Germany info@ratiopharm.de 
Nemčija info@ratiopharm.de
Brampton Road, Hampden Park, Eastbourne East Sussex, BN22 9AG United Kingdom 
Brampton Road, Hampden Park, Eastbourne East Sussex, BN22 9AG Velika Britanija
If you forget to take Desloratadine ratiopharm If you forget to take your dose on time, take it as soon as possible and then go back to your regular dosing schedule. 
Če ste pozabili vzeti zdravilo Desloratadin ratiopharm Če ste pozabili vzeti odmerek pravočasno, ga vzemite čimprej in potem nadaljujte z ustaljenim režimom odmerjanja.
Each tablet contains 14.25 mg of lactose (as monohydrate). 
Ena tableta vsebuje 14,25 mg laktoze (v obliki monohidrata).
Date of latest renewal: 8 August 2016 
Datum prve odobritve: 13. januar 2012 Datum zadnjega podaljšanja: 8. avgust 2016
For urticaria, the duration of treatment may be variable from patient to patient and therefore you should follow the instructions of your doctor. 
Pri urtikariji se lahko potrebna dolžina zdravljenja razlikuje od bolnika do bolnika, zato upoštevajte navodila svojega zdravnika.
305 74770 Opava-Komárov Czech Republic 
305 74770 Opava-Komárov Češka
The most frequent of adverse reactions reported in excess of placebo were fatigue (1.2 %), dry mouth (0.8 %) and headache (0.6 %). 
Najpogostejši neželeni učinki, katerih pogostnost je bila večja kot pri placebu, so bili utrujenost (1,2 %), suha usta (0,8 %) in glavobol (0,6 %).
7 film-coated tablets 10 film-coated tablets 14 film-coated tablets 15 film-coated tablets 20 film-coated tablets 30 film-coated tablets 40 film-coated tablets 50 film-coated tablets 60 film-coated tablets 90 film-coated tablets 100 film-coated tablets 
7 filmsko obloženih tablet 10 filmsko obloženih tablet 14 filmsko obloženih tablet 15 filmsko obloženih tablet 20 filmsko obloženih tablet 30 filmsko obloženih tablet 40 filmsko obloženih tablet 50 filmsko obloženih tablet 60 filmsko obloženih tablet 90 filmsko obloženih tablet 100 filmsko obloženih tablet
Desloratadine does not inhibit CYP3A4 in vivo, and in vitro studies have shown that the medicinal product does not inhibit CYP2D6 and is neither a substrate nor an inhibitor of P-glycoprotein. 
Desloratadin ne zavira encima CYP3A4 in vivo, in vitro študije pa so pokazale, da zdravilo tudi ne inhibira encima CYP2D6 in da ni ne substrat ne inhibitor P-glikoproteina.
The efficacy of desloratadine tablets has not been clearly demonstrated in trials with adolescent patients 12 through 17 years of age. 
Učinkovitosti tablet desloratadina niso jasno dokazali v preskušanjih pri mladostnikih, starih od 12 do 17 let.
Treatment with desloratadine also significantly reduced interference with sleep and daytime function, as measured by a four-point scale used to assess these variables. 
Zdravljenje z desloratadinom je tudi bistveno zmanjšalo motnje spanja in dnevnih dejavnosti bolnika čez dan, kar so ugotavljali na podlagi meritev s štiritočkovno lestvico za oceno teh spremenljivk.
Regarding the duration of treatment, your doctor will determine the type of allergic rhinitis you are suffering from and will determine for how long you should take Desloratadine ratiopharm. 
Kar zadeva trajanje zdravljenja, bo vaš zdravnik najprej ugotovil vrsto alergijskega rinitisa, ki jo imate, in na podlagi tega določil, kako dolgo naj bi jemali zdravilo Desloratadin ratiopharm.
ratiopharm GmbH Graf-Arco-Straße 3 89079 Ulm Germany info@ratiopharm.de 
ratiopharm GmbH Graf-Arco-Straße 3 89079 Ulm Nemčija info@ratiopharm.de
305, 74770 Opava-Komarov Czech Republic 
305, 74770 Opava-Komarov Češka
• if you have poor kidney function. 
• če vam ledvice slabo delujejo.
Pharmacotherapeutic group: antihistamines - H1 antagonist, ATC code: R06A X27 
Farmakoterapevtska skupina: antihistaminiki za sistemsko zdravljenje - antagonist H1 receptorjev, oznaka ATC: R06A X27
Desloratadine ratiopharm with food, drink and alcohol Desloratadine ratiopharm may be taken with or without a meal. 
Zdravilo Desloratadin ratiopharm skupaj s hrano, pijačo in alkoholom Zdravilo Desloratadin ratiopharm se lahko jemlje s hrano ali brez nje.
Marketing Authorisation Holder ratiopharm GmbH Graf-Arco-Straße 3 
Imetnik dovoljenja za promet ratiopharm GmbH Graf-Arco-Straße 3
Desloratadine is not eliminated by haemodialysis; it is not known if it is eliminated by peritoneal dialysis. 
Desloratadina iz telesa ni mogoče odstraniti s hemodializo in ni znano, ali se lahko odstrani s peritonealno dializo.
In two placebo-controlled six week trials in patients with chronic idiopathic urticaria, desloratadine was effective in relieving pruritus and decreasing the size and number of hives by the end of the first dosing interval. 
V dveh s placebom kontroliranih šesttedenskih preskušanjih pri bolnikih s kronično idiopatsko urtikarijo je desloratadin učinkovito blažil srbenje in zmanjšal velikost in število izpuščajev koprivnice že do konca prvega intervala odmerjanja.
The lack of carcinogenic potential was demonstrated in studies conducted with desloratadine and loratadine. 
Odsotnost kancerogenih učinkov so pokazali v raziskavah z desloratadinom in loratadinom.
These include inhibiting the release of proinflammatory cytokines such as IL-4, IL-6, IL-8, and IL-13 from human mast cells/basophils, as well as inhibition of the expression of the adhesion molecule P-selectin on endothelial cells. 
Gre za inhibicijo sproščanja vnetnih citokinov, kakor so npr. IL-4, IL-6, IL-8 in IL-13 iz človeških mastocitov ali bazofilcev, pa tudi za inhibicijo ekspresije adhezijske molekule P-selektina na endotelijskih celicah.
Hypersensitivity to the active substance, to any of the excipients listed in section 6.1 or to loratadine. 
Preobčutljivost na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1, ali loratadin.
Desloratadine is a non-sedating, long-acting histamine antagonist with selective peripheral H1-receptor antagonist activity. 
Desloratadin je nesedativen, dolgodelujoč histaminski antagonist s selektivnim antagonističnim delovanjem na periferne histaminske receptorje H1.
Desloratadine ratiopharm 5 mg film-coated tablets are supplied in PVC/PVdC/aluminium blister packs of 7, 10, 14, 15, 20, 30, 40, 50, 60, 90 and 100 film-coated tablets. 
5 mg filmsko obložene tablete Desloratadin ratiopharm so na voljo v pretisnem omotu PVC/PVdC/aluminij v pakiranjih po 7, 10, 14, 15, 20, 30, 40, 50, 60, 90 ali 100 filmsko obloženih tablet.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Desloratadine ratiopharm 5 mg film-coated tablets therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman. 
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilo Desloratadin ratiopharm 5 mg filmsko obložene tablete, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
What Desloratadine ratiopharm is and what it is used for What you need to know before you take Desloratadine ratiopharm How to take Desloratadine ratiopharm Possible side effects 
Kaj je zdravilo Desloratadin ratiopharm in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Desloratadin ratiopharm Kako jemati zdravilo Desloratadin ratiopharm Možni neželeni učinki
The safety and efficacy of Desloratadine ratiopharm 5 mg film-coated tablets in children below the age of 12 years have not been established. 
Varnost in učinkovitost zdravilo Desloratadin ratiopharm 5 mg filmsko obložene tablete pri otrocih, mlajših od 12 let, nista bili dokazani.
If you stop taking Desloratadine ratiopharm If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 
Če ste prenehali jemati zdravilo Desloratadin ratiopharm Če imate dodatna vprašanja o uporabi zdravila, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
Adverse reactions seen with desloratadine 
Neželeni učinki opaženi pri desloratadinu
Desloratadine ratiopharm 5 mg film-coated tablets is indicated in adults and adolescents aged 12 years and older for the relief of symptoms associated with: - allergic rhinitis (see section 5.1) - urticaria (see section 5.1) 
Zdravilo Desloratadin ratiopharm 5 mg filmsko obložene tablete je indicirano pri odraslih in mladostnikih, starih 12 let in več, za lajšanje simptomov: - alergijskega rinitisa (glejte poglavje 5.1) - urtikarije (glejte poglavje 5.1)
Other medicines and Desloratadine ratiopharm There are no known interactions of Desloratadine ratiopharm with other medicines. 
Druga zdravila in zdravilo Desloratadin ratiopharm Ni znanih interakcij med zdravilom Desloratadin ratiopharm in drugimi zdravili.
• if you have medical or familial history of seizures. 
• če ste imeli v preteklosti vi ali kdo v vaši družini epileptične napade.
METHOD AND ROUTE(S) OF ADMINISTRATION Swallow the tablet whole with water. 
POSTOPEK IN POT(I) UPORABE ZDRAVILA Tableto pogoltnite celo z vodo.
In a single dose study performed in adults, desloratadine 5 mg did not affect standard measures of flight performance including exacerbation of subjective sleepiness or tasks related to flying. 
V študiji enkratnega odmerka pri odraslih desloratadin v odmerku 5 mg ni vplival na standardna merila uspešnosti pilotiranja, vključno s subjektivnim poslabšanjem zaspanosti ali opravili pri pilotiranju.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg desloratadine. 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena tableta vsebuje 5 mg desloratadina.
Taking Desloratadine ratiopharm is not recommended if you are pregnant or nursing a baby. 
Jemanja zdravila Desloratadin ratiopharm vam ne priporočamo, če ste noseči ali če dojite.
Round, biconvex, blue film-coated tablets. 
Okrogla, bikonveksna, modra filmsko obložena tableta.
In the case of severe renal insufficiency, Desloratadine ratiopharm 5 mg film-coated tablets should be used with caution (see section 5.2). 
V primeru hude ledvične insuficience morate zdravilo Desloratadin ratiopharm 5 mg filmsko obložene tablete uporabljati previdno (glejte poglavje 5.2).
● increased sensitivity of the skin to the sun, even in case of hazy sun, and to UV light, for instance to 
● povečana občutljivost kože za sonce, tudi če gre za indirektno izpostavljenost soncu (čez oblake,
INFORMATION IN BRAILLE Desloratadine ratiopharm 5 mg 17. 
PODATKI O BRAILLOVI PISAVI Desloratadin ratiopharm 5 mg17.
During the marketing of Desloratadine ratiopharm, cases of severe allergic reactions (difficulty in breathing, wheezing, itching, hives and swelling) have been reported very rarely. 
Med trženjem zdravila Desloratadin ratiopharm so zelo redko poročali o primerih hudih alergijskih reakcij (težave z dihanjem, piskanje, srbenje, koprivnica in otekanje).
What Desloratadine ratiopharm looks like and contents of the pack Round, biconvex, blue film-coated tablets. 
Izgled zdravila Desloratadin ratiopharm in vsebina pakiranja Okrogle, bikonveksne, modre filmsko obložene tablete.
In clinical trials in a range of indications including allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, undesirable effects with desloratadine were reported in 3 % of patients in excess of those treated with placebo. 
V kliničnih preskušanjih pri različnih indikacijah za uporabo zdravila, vključno z alergijskim rinitisom in kronično idiopatsko urtikarijo so pri priporočenem odmerku 5 mg na dan desloratadina o neželenih učinkih poročali pri 3 % bolnikov več kot pri tistih, ki so bili zdravljeni s placebom.
Adults During the marketing of Desloratadine ratiopharm, the following side effects were reported as: 
Odrasli Med trženjem zdravila Desloratadin ratiopharm so poročali o naslednjih neželenih učinkih:
As with other antihistamine trials in chronic idiopathic urticaria, the minority of patients who were identified as non-responsive to antihistamines was excluded. 
Kot pri drugih preskušanjih uporabe antihistaminikov pri bolnikih s kronično idiopatsko urtikarijo so iz raziskave izločili manjše število bolnikov, za katere je bilo ugotovljeno, da se ne odzivajo na antihistaminike.
Desloratadine ratiopharm is also used to relieve the symptoms associated with urticaria (a skin condition caused by an allergy). 
Zdravilo Desloratadin ratiopharm se uporablja tudi za lajšanje simptomov urtikarije, (težave s kožo zaradi alergije).
2D barcode carrying the unique identifier included. 
ČRTNA KODA Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
6.5 Nature and contents of container PVC/PVdC/aluminium blister: 
PVC/PVdC/aluminij
Poloxamer type 188 Citric acid monohydrate Microcrystalline cellulose Maize starch 
poloksamer tipa 188 citronska kislina monohidrat mikrokristalna celuloza koruzni škrob premreženi natrijev karmelozat laktoza monohidrat smukec
Hallucinations Abnormal behaviour, aggression 
Psihiatrične motnje zelo redki neznana halucinacije nenormalno vedenje, agresivnost
If you take more Desloratadine ratiopharm than you should 
Če ste vzeli večji odmerek zdravila Desloratadin ratiopharm, kot bi smeli
What Desloratadine ratiopharm is and what it is used for 
Kaj je zdravilo Desloratadin ratiopharm in za kaj ga uporabljamo
The recommended dose of Desloratadine ratiopharm 5 mg film-coated tablets is one tablet once a day. 
Priporočeni odmerek zdravilo Desloratadin ratiopharm 5 mg filmsko obložene tablete je ena tableta enkrat na dan.
How to store Desloratadine ratiopharm Contents of the pack and other information 
Shranjevanje zdravila Desloratadin ratiopharm Vsebina pakiranja in dodatne informacije
Tablet core: poloxamer type 188, citric acid monohydrate, microcrystalline cellulose, maize starch, croscarmellose sodium, lactose monohydrate (see section 2 “Desloratadine ratiopharm contains lactose”), talc, 
Jedro tablete: poloksamer tipa 188, citronska kislina monohidrat, mikrokristalna celuloza, koruzni škrob, premreženi natrijev karmelozat, laktoza monohidrat (glejte poglavje 2 "Zdravilo Desloratadin ratiopharm vsebuje laktozo"), smukec.
In a clinical pharmacology trial, in which desloratadine was administered at a dose of 45 mg daily (nine times the clinical dose) for ten days, no prolongation of QTc interval was seen. 
V kliničnem farmakološkem preskušanju, pri katerem so bolniki jemali desloratadin v odmerku 45 mg na dan (9-kratni klinični odmerek) 10 dni, niso opažali podaljšanja QTc intervala.
31-546 Krakow 
Mogilska 80. 31-546 Krakow
Pack sizes of 7, 10, 14, 15, 20, 30, 40, 50, 60, 90 and 100 film-coated tablets. 
PVC/PVdC/aluminijasti pretisni omoti: pakiranja po 7, 10, 14, 15, 20, 30, 40, 50, 60, 90 ali 100 filmsko obloženih tablet.
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu. 
Navodilo je bilo nazadnje revidirano dne {MM/LLLL} Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila: http://www.ema.europa.eu.
In patients with allergic rhinitis, desloratadine was effective in relieving symptoms such as sneezing, nasal discharge and itching, as well as ocular itching, tearing and redness, and itching of palate. 
Pri bolnikih z alergijskim rinitisom deslortadin učinkovito lajša simptome, kakor so kihanje, izcedek iz nosu in srbenje, pa tudi srbenje oči, solzenje in vnetje očesne veznice ter srbenje ustnega neba.
Film-coating: polyvinyl alcohol (part. hydrolysed), titanium dioxide (E171), macrogol/PEG 3350, talc and indigo carmine aluminium lake (E132). 
Obloga tablete: polivinilaklohol (deloma hidroliziran), titanov dioksid (E171), makrogol/PEG 3350, smukec, indigotin (E132).
Desloratadine ratiopharm is an antiallergy medicine that does not make you drowsy. 
Zdravilo Desloratadin ratiopharm je zdravilo proti alergiji, ki ne povzroča zaspanosti.
These symptoms include sneezing, runny or itchy nose, itchy palate, and itchy, red or watery eyes. 
Ti simptomi vključujejo kihanje, izcedek iz nosu ali srbenje nosu, srbenje ustnega neba in oči, vnetje očesne veznice, rdeče ali solzne oči.
In a clinical pharmacology trial desloratadine tablets taken concomitantly with alcohol did not potentiate the performance impairing effects of alcohol (see section 5.1). 
V klinični farmakološki raziskavi pri sočasnem jemanju tablet desloratadina in uživanju alkohola ni bilo okrepljenih škodljivih učinkov alkohola (glejte poglavje 5.1).
UNIQUE IDENTIFIER - 2D BARCODE 
EDINSTVENA OZNAKA - DVODIMENZIONALNA
What Desloratadine ratiopharm is Desloratadine ratiopharm contains desloratadine which is an antihistamine. 
Kaj je zdravilo Desloratadin ratiopharm Zdravilo Desloratadin ratiopharm vsebuje desloratadin, ki je antihistaminik.
Desloratadine has no or negligible influence on the ability to drive and use machines based on clinical trials. 
Desloratadin glede na klinične študije nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
In clinical pharmacology trials, co-administration with alcohol did not increase the alcohol-induced impairment in performance or increase in sleepiness. 
V kliničnih farmakoloških preskušanjih sočasna uporaba desloratadina z alkoholom ni okrepila škodljivega vpliva alkohola na psihomotorične sposobnosti ali povečala zaspanosti pri bolnikih.
- If you have any further questions, ask your doctor, pharmacist or nurse. 
- Če imate dodatna vprašanja, se posvetujte z zdravnikom ali farmacevtom ali medicinsko sestro.
Desloratadine given at a single daily dose of 7.5 mg did not affect psychomotor performance in clinical trials. 
V kliničnih preskušanjih desloratadin v enem dnevnem odmerku 7,5 mg ni vplival na psihomotorične sposobnosti bolnikov.
Polyvinyl alcohol (part. hydrolysed) Titanium dioxide (E171) Macrogol/PEG 3350 
Obloga tablete: polivinilaklohol (deloma hidroliziran) titanov dioksid (E171) makrogol/PEG 3350 smukec indigotin (E132)
In persistent allergic rhinitis (presence of symptoms for 4 days or more per week and for more than 4 weeks), continued treatment may be proposed to the patients during the allergen exposure periods. 
Pri perzistentnem alergijskem rinitisu (kadar so simptomi prisotni 4 dni ali več na teden in dlje kot 4 tedne), lahko bolnikom predlagate nadaljevanje zdravljenja tudi v času izpostavljenosti alergenom.
In clinical studies with desloratadine, the following side effects were reported as: 
V kliničnih študijah z zdravilom Desloratadin ratiopharm so poročali o naslednjih neželenih učinkih:
As a precautionary measure, it is preferable to avoid the use of Desloratadine ratiopharm 5 mg film-coated tablets during pregnancy. 
Iz previdnostnih razlogov se je med nosečnostjo uporabi zdravilo Desloratadin ratiopharm 5 mg filmsko obložene tablete bolje izogibati.
Use caution when taking Desloratadine ratiopharm with alcohol. 
Pri sočasnem jemanju zdravila Desloratadin ratiopharm in uživanju alkohola je potrebna previdnost.
PHARMACEUTICAL PARTICULARS 6.1 List of excipients 
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi Jedro tablete: